Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leukemia group B study
The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Both drugs were administered to 76 eligible patients...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer & clinical oncology 1990, Vol.26 (10), p.1057-1060 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1060 |
|---|---|
| container_issue | 10 |
| container_start_page | 1057 |
| container_title | European journal of cancer & clinical oncology |
| container_volume | 26 |
| creator | Kreisman, Harvey Goutsou, Maria Modeas, Caron Graziano, Stephen L. Costanza, Mary E. Green, Mark R. |
| description | The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Both drugs were administered to 76 eligible patients with advanced NSCLC. No patient had been previously treated with chemotherapy. Cisplatin 50 mg/m
2 and carboplatin 350 mg/m
2 were administered every 28 days until disease progression occurred. There was 1 complete response and the overall response rate among the 68 evaluable for response patients was 13%. Neither histological subtype nor initial performance status was a significant factor influencing response. Median survival was 5.1 months with significant differences based on initial performance status but not on histological subtype. Severe or life-threatening leukopenia and thrombocytopenia occurred in 23% and 36% of the 76 patients, respectively. There were 2 toxic deaths, 1 each due to infection and haemorrhage. The efficacy of this combination is not different from that of carboplatin alone, and the combination may be of greater benefit in patients with more responsive tumours than NSCLC. |
| doi_str_mv | 10.1016/0277-5379(90)90051-T |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16628909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>027753799090051T</els_id><sourcerecordid>16628909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-83befdc414f41239e5d3195052c587b54d851da7586e40398bbed3d9e46cd4833</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVoSTZp_0EDOpSSHtxKlmRJORTapV8QyGV7FrI0TpX4K5Iduv8-ctbssZeZF-aZYXgQekfJJ0po9ZmUUhaCSX2lyUdNiKDF7gRtqJK6IEqUr9DmiJyh85TuCSkVF-wUnZZUSsarDbrfhjS2dgp94Wysh0PG01-IdtzjHOHfBH0KT4D7oS9SZ9sWO8ilnfs77GzvIF5juyZse49bmB-gCxbfxWEe8Tecptnv36DXjW0TvF37Bfrz4_tu-6u4uf35e_v1pnCcyqlQrIbG58wbTkumQXhGtSCidELJWnCvBPVWClUBJ0yrugbPvAZeOc8VYxfow-HuGIfHGdJkupCWj20Pw5wMrapSaaIzyA-gi0NKERozxtDZuDeUmEWxWfyZxZ_RxLwoNru8drnen-sO_HFpdZrn79e5Tc62TcxiQjpiXJeVFAv25YBBdvEUIJrkAmSHPkRwk_FD-P8fz8WkmEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16628909</pqid></control><display><type>article</type><title>Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leukemia group B study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kreisman, Harvey ; Goutsou, Maria ; Modeas, Caron ; Graziano, Stephen L. ; Costanza, Mary E. ; Green, Mark R.</creator><creatorcontrib>Kreisman, Harvey ; Goutsou, Maria ; Modeas, Caron ; Graziano, Stephen L. ; Costanza, Mary E. ; Green, Mark R.</creatorcontrib><description>The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Both drugs were administered to 76 eligible patients with advanced NSCLC. No patient had been previously treated with chemotherapy. Cisplatin 50 mg/m
2 and carboplatin 350 mg/m
2 were administered every 28 days until disease progression occurred. There was 1 complete response and the overall response rate among the 68 evaluable for response patients was 13%. Neither histological subtype nor initial performance status was a significant factor influencing response. Median survival was 5.1 months with significant differences based on initial performance status but not on histological subtype. Severe or life-threatening leukopenia and thrombocytopenia occurred in 23% and 36% of the 76 patients, respectively. There were 2 toxic deaths, 1 each due to infection and haemorrhage. The efficacy of this combination is not different from that of carboplatin alone, and the combination may be of greater benefit in patients with more responsive tumours than NSCLC.</description><identifier>ISSN: 0277-5379</identifier><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/0277-5379(90)90051-T</identifier><identifier>PMID: 2177346</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - toxicity ; Biological and medical sciences ; Carboplatin - administration & dosage ; Carboplatin - toxicity ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Cisplatin - administration & dosage ; Cisplatin - toxicity ; Drug Evaluation ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Medical sciences ; Middle Aged ; Pneumology</subject><ispartof>European journal of cancer & clinical oncology, 1990, Vol.26 (10), p.1057-1060</ispartof><rights>1990</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-83befdc414f41239e5d3195052c587b54d851da7586e40398bbed3d9e46cd4833</citedby><cites>FETCH-LOGICAL-c417t-83befdc414f41239e5d3195052c587b54d851da7586e40398bbed3d9e46cd4833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4926756$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2177346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kreisman, Harvey</creatorcontrib><creatorcontrib>Goutsou, Maria</creatorcontrib><creatorcontrib>Modeas, Caron</creatorcontrib><creatorcontrib>Graziano, Stephen L.</creatorcontrib><creatorcontrib>Costanza, Mary E.</creatorcontrib><creatorcontrib>Green, Mark R.</creatorcontrib><title>Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leukemia group B study</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer</addtitle><description>The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Both drugs were administered to 76 eligible patients with advanced NSCLC. No patient had been previously treated with chemotherapy. Cisplatin 50 mg/m
2 and carboplatin 350 mg/m
2 were administered every 28 days until disease progression occurred. There was 1 complete response and the overall response rate among the 68 evaluable for response patients was 13%. Neither histological subtype nor initial performance status was a significant factor influencing response. Median survival was 5.1 months with significant differences based on initial performance status but not on histological subtype. Severe or life-threatening leukopenia and thrombocytopenia occurred in 23% and 36% of the 76 patients, respectively. There were 2 toxic deaths, 1 each due to infection and haemorrhage. The efficacy of this combination is not different from that of carboplatin alone, and the combination may be of greater benefit in patients with more responsive tumours than NSCLC.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - toxicity</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - toxicity</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - toxicity</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><issn>0277-5379</issn><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVoSTZp_0EDOpSSHtxKlmRJORTapV8QyGV7FrI0TpX4K5Iduv8-ctbssZeZF-aZYXgQekfJJ0po9ZmUUhaCSX2lyUdNiKDF7gRtqJK6IEqUr9DmiJyh85TuCSkVF-wUnZZUSsarDbrfhjS2dgp94Wysh0PG01-IdtzjHOHfBH0KT4D7oS9SZ9sWO8ilnfs77GzvIF5juyZse49bmB-gCxbfxWEe8Tecptnv36DXjW0TvF37Bfrz4_tu-6u4uf35e_v1pnCcyqlQrIbG58wbTkumQXhGtSCidELJWnCvBPVWClUBJ0yrugbPvAZeOc8VYxfow-HuGIfHGdJkupCWj20Pw5wMrapSaaIzyA-gi0NKERozxtDZuDeUmEWxWfyZxZ_RxLwoNru8drnen-sO_HFpdZrn79e5Tc62TcxiQjpiXJeVFAv25YBBdvEUIJrkAmSHPkRwk_FD-P8fz8WkmEg</recordid><startdate>1990</startdate><enddate>1990</enddate><creator>Kreisman, Harvey</creator><creator>Goutsou, Maria</creator><creator>Modeas, Caron</creator><creator>Graziano, Stephen L.</creator><creator>Costanza, Mary E.</creator><creator>Green, Mark R.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>1990</creationdate><title>Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leukemia group B study</title><author>Kreisman, Harvey ; Goutsou, Maria ; Modeas, Caron ; Graziano, Stephen L. ; Costanza, Mary E. ; Green, Mark R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-83befdc414f41239e5d3195052c587b54d851da7586e40398bbed3d9e46cd4833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - toxicity</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - toxicity</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - toxicity</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kreisman, Harvey</creatorcontrib><creatorcontrib>Goutsou, Maria</creatorcontrib><creatorcontrib>Modeas, Caron</creatorcontrib><creatorcontrib>Graziano, Stephen L.</creatorcontrib><creatorcontrib>Costanza, Mary E.</creatorcontrib><creatorcontrib>Green, Mark R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kreisman, Harvey</au><au>Goutsou, Maria</au><au>Modeas, Caron</au><au>Graziano, Stephen L.</au><au>Costanza, Mary E.</au><au>Green, Mark R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leukemia group B study</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer</addtitle><date>1990</date><risdate>1990</risdate><volume>26</volume><issue>10</issue><spage>1057</spage><epage>1060</epage><pages>1057-1060</pages><issn>0277-5379</issn><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Both drugs were administered to 76 eligible patients with advanced NSCLC. No patient had been previously treated with chemotherapy. Cisplatin 50 mg/m
2 and carboplatin 350 mg/m
2 were administered every 28 days until disease progression occurred. There was 1 complete response and the overall response rate among the 68 evaluable for response patients was 13%. Neither histological subtype nor initial performance status was a significant factor influencing response. Median survival was 5.1 months with significant differences based on initial performance status but not on histological subtype. Severe or life-threatening leukopenia and thrombocytopenia occurred in 23% and 36% of the 76 patients, respectively. There were 2 toxic deaths, 1 each due to infection and haemorrhage. The efficacy of this combination is not different from that of carboplatin alone, and the combination may be of greater benefit in patients with more responsive tumours than NSCLC.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>2177346</pmid><doi>10.1016/0277-5379(90)90051-T</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-5379 |
| ispartof | European journal of cancer & clinical oncology, 1990, Vol.26 (10), p.1057-1060 |
| issn | 0277-5379 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16628909 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antineoplastic Combined Chemotherapy Protocols - toxicity Biological and medical sciences Carboplatin - administration & dosage Carboplatin - toxicity Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Cisplatin - administration & dosage Cisplatin - toxicity Drug Evaluation Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medical sciences Middle Aged Pneumology |
| title | Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leukemia group B study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T00%3A00%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cisplatin-carboplatin%20therapy%20in%20extensive%20non-small%20cell%20lung%20cancer:%20a%20cancer%20and%20leukemia%20group%20B%20study&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Kreisman,%20Harvey&rft.date=1990&rft.volume=26&rft.issue=10&rft.spage=1057&rft.epage=1060&rft.pages=1057-1060&rft.issn=0277-5379&rft.eissn=1879-0852&rft_id=info:doi/10.1016/0277-5379(90)90051-T&rft_dat=%3Cproquest_cross%3E16628909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16628909&rft_id=info:pmid/2177346&rft_els_id=027753799090051T&rfr_iscdi=true |